Literature DB >> 18397267

Differential regulation of SOCS-1 signalling in B and T lymphocytes by hepatitis C virus core protein.

Zhi Qiang Yao1, Deborah Prayther, Christopher Trabue, Zhi Ping Dong, Jonathan Moorman.   

Abstract

Hepatitis C virus (HCV) infection is characterized by a strong propensity toward chronicity, autoimmune phenomena and lymphomagenesis, supporting a role for lymphocyte dysregulation during persistent viral infection. We have shown that HCV core protein inhibits T-cell functions through interaction with a complement receptor, gC1qR. Here, we further report that B cells also express gC1qR that can be bound by HCV core protein. Importantly, using flow cytometry, we demonstrated differential regulation of B and T lymphocytes by the HCV core-gC1qR interaction, with down-regulation of CD69 activation in T cells but up-regulation of CD69 activation and cell proliferation in B cells. HCV core treatment led to decreased interferon-gamma production in CD8+ T cells but to increased immunoglobulin M and immunoglobulin G production as well as cell surface expression of costimulatory and chemokine receptors, including CD86 (B7-2), CD154 (CD40L) and CD195 (CCR5), in CD20+ B cells. Finally, we showed down-regulation of suppressor of cytokine signalling-1 (SOCS-1) using real-time reverse transcription-polymerase chain reaction, accompanied by up-regulation of signal transducer and activator of transcription-1 (STAT1) phosphorylation in B cells in response to HCV core protein, with the opposite pattern observed in HCV core-treated T cells. This study demonstrates differential regulation of B and T lymphocytes by HCV core and supports a mechanism by which lymphocyte dysregulation occurs in the course of persistent HCV infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18397267      PMCID: PMC2561140          DOI: 10.1111/j.1365-2567.2008.02829.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  40 in total

1.  Hepatitis C: the complications of immune dysfunction.

Authors:  Ellis King; Christopher Trabue; Deling Yin; Zhi Q Yao; Jonathan P Moorman
Journal:  Expert Rev Clin Immunol       Date:  2007-03       Impact factor: 4.473

2.  Effects of combined antiviral therapy on asymptomatic mixed cryoglobulinemia in naive patients with chronic hepatitis C virus infection: a preliminary study.

Authors:  Emilio D'Amico; Caterina Chincoli; Pierluigi Cacciatore; Gabriella di Pasqua; Luana Cosentino; Giuseppe Riario-Sforza; Ernesta Pennese; Fabio Capani; Carlo Palazzi
Journal:  Dig Dis Sci       Date:  2005-12       Impact factor: 3.199

3.  Detection of hepatitis C virus core protein circulating within different virus particle populations.

Authors:  O V Masalova; S N Atanadze; E I Samokhvalov; N V Petrakova; T I Kalinina; V D Smirnov; Y E Khudyakov; H A Fields; A A Kushch
Journal:  J Med Virol       Date:  1998-05       Impact factor: 2.327

4.  Risk of non-Hodgkin's lymphoma in patients with hepatitis C virus infection.

Authors:  M Ohsawa; N Shingu; H Miwa; H Yoshihara; M Kubo; H Tsukuma; H Teshima; M Hashimoto; K Aozasa
Journal:  Int J Cancer       Date:  1999-01-18       Impact factor: 7.396

5.  Hepatitis C and B-cell lymphoma.

Authors:  A Kashyap; A Nademanee; A Molina
Journal:  Ann Intern Med       Date:  1998-04-15       Impact factor: 25.391

Review 6.  Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations.

Authors:  Domenico Sansonno; Franco Dammacco
Journal:  Lancet Infect Dis       Date:  2005-04       Impact factor: 25.071

7.  Signals transducers and activators of transcription (STAT)-induced STAT inhibitor-1 (SSI-1)/suppressor of cytokine signaling-1 (SOCS-1) suppresses tumor necrosis factor alpha-induced cell death in fibroblasts.

Authors:  Y Morita; T Naka; Y Kawazoe; M Fujimoto; M Narazaki; R Nakagawa; H Fukuyama; S Nagata; T Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

8.  Interferon plus ribavirin in patients with hepatitis C virus positive mixed cryoglobulinemia resistant to interferon.

Authors:  Cesare Mazzaro; Francesca Zorat; Consuelo Comar; Fabiana Nascimben; Dario Bianchini; Stefano Baracetti; Carlo Donada; Valter Donadon; Gabriele Pozzato
Journal:  J Rheumatol       Date:  2003-08       Impact factor: 4.666

9.  Human T cells express specific binding sites for C1q. Role in T cell activation and proliferation.

Authors:  A Chen; S Gaddipati; Y Hong; D J Volkman; E I Peerschke; B Ghebrehiwet
Journal:  J Immunol       Date:  1994-08-15       Impact factor: 5.422

10.  Differential hypermethylation of SOCS genes in ovarian and breast carcinomas.

Authors:  Kate D Sutherland; Geoffrey J Lindeman; David Y H Choong; Sergio Wittlin; Luci Brentzell; Wayne Phillips; Ian G Campbell; Jane E Visvader
Journal:  Oncogene       Date:  2004-10-07       Impact factor: 9.867

View more
  33 in total

1.  PD-1 negatively regulates interleukin-12 expression by limiting STAT-1 phosphorylation in monocytes/macrophages during chronic hepatitis C virus infection.

Authors:  Cheng J Ma; Lei Ni; Ying Zhang; C L Zhang; Xiao Y Wu; Antwan N Atia; Penny Thayer; Jonathan P Moorman; Zhi Q Yao
Journal:  Immunology       Date:  2010-11-23       Impact factor: 7.397

2.  Protection of CD4+ T cells from hepatitis C virus infection-associated senescence via ΔNp63-miR-181a-Sirt1 pathway.

Authors:  Yun Zhou; Guang Y Li; Jun P Ren; Ling Wang; Juan Zhao; Shun B Ning; Ying Zhang; Jian Q Lian; Chang X Huang; Zhan S Jia; Jonathan P Moorman; Zhi Q Yao
Journal:  J Leukoc Biol       Date:  2016-06-27       Impact factor: 4.962

3.  Impaired hepatitis B vaccine responses during chronic hepatitis C infection: involvement of the PD-1 pathway in regulating CD4(+) T cell responses.

Authors:  Jonathan P Moorman; Chun L Zhang; Lei Ni; Cheng J Ma; Ying Zhang; Xiao Y Wu; Penny Thayer; Tareq M Islam; Thomas Borthwick; Zhi Q Yao
Journal:  Vaccine       Date:  2011-03-03       Impact factor: 3.641

4.  Tim-3 pathway controls regulatory and effector T cell balance during hepatitis C virus infection.

Authors:  Jonathan P Moorman; Jia M Wang; Ying Zhang; Xiao J Ji; Cheng J Ma; Xiao Y Wu; Zhan S Jia; Ke S Wang; Zhi Q Yao
Journal:  J Immunol       Date:  2012-06-15       Impact factor: 5.422

5.  SOCS proteins in development and disease.

Authors:  Monique C Trengove; Alister C Ward
Journal:  Am J Clin Exp Immunol       Date:  2013-02-27

6.  Programmed death-1 affects suppressor of cytokine signaling-1 expression in T cells during hepatitis C infection.

Authors:  Ashley D Frazier; Chun L Zhang; Lei Ni; Cheng J Ma; Ying Zhang; Xiao Y Wu; Antwan N Atia; Zhi Q Yao; Jonathan P Moorman
Journal:  Viral Immunol       Date:  2010-10       Impact factor: 2.257

Review 7.  Viral exploitation of host SOCS protein functions.

Authors:  Lisa Nowoslawski Akhtar; Etty N Benveniste
Journal:  J Virol       Date:  2010-11-17       Impact factor: 5.103

8.  Tim-3 alters the balance of IL-12/IL-23 and drives TH17 cells: role in hepatitis B vaccine failure during hepatitis C infection.

Authors:  Jia M Wang; Cheng J Ma; Guang Y Li; Xiao Y Wu; Penny Thayer; Pamela Greer; Ashley M Smith; Kevin P High; Jonathan P Moorman; Zhi Q Yao
Journal:  Vaccine       Date:  2013-03-14       Impact factor: 3.641

Review 9.  Immune exhaustion and immune senescence: two distinct pathways for HBV vaccine failure during HCV and/or HIV infection.

Authors:  Zhi Q Yao; Jonathan P Moorman
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2013-02-12       Impact factor: 4.291

10.  Role of the receptor for the globular domain of C1q protein in the pathogenesis of hepatitis C virus-related cryoglobulin vascular damage.

Authors:  Domenico Sansonno; Felicia Anna Tucci; Berhane Ghebrehiwet; Gianfranco Lauletta; Ellinor I B Peerschke; Vincenza Conteduca; Sabino Russi; Pietro Gatti; Loredana Sansonno; Franco Dammacco
Journal:  J Immunol       Date:  2009-10-14       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.